ATE441631T1 - Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer - Google Patents

Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer

Info

Publication number
ATE441631T1
ATE441631T1 AT06016609T AT06016609T ATE441631T1 AT E441631 T1 ATE441631 T1 AT E441631T1 AT 06016609 T AT06016609 T AT 06016609T AT 06016609 T AT06016609 T AT 06016609T AT E441631 T1 ATE441631 T1 AT E441631T1
Authority
AT
Austria
Prior art keywords
reuppost
serotonin
inhibitors
phenylpiperidine derivatives
phenylpiperidine
Prior art date
Application number
AT06016609T
Other languages
English (en)
Inventor
Thomas Ruhland
Garrick Paul Smith
Benny Bang-Andersen
Ask Puschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE441631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE441631T1 publication Critical patent/ATE441631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
AT06016609T 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer ATE441631T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
ATE441631T1 true ATE441631T1 (de) 2009-09-15

Family

ID=8160750

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06016609T ATE441631T1 (de) 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
AT02800051T ATE386730T1 (de) 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02800051T ATE386730T1 (de) 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Country Status (39)

Country Link
US (10) US7144884B2 (de)
EP (2) EP1749818B1 (de)
JP (3) JP3896116B2 (de)
KR (3) KR100842702B1 (de)
CN (1) CN1319958C (de)
AR (2) AR036659A1 (de)
AT (2) ATE441631T1 (de)
AU (2) AU2002333220C1 (de)
BE (1) BE2014C036I2 (de)
BR (3) BRPI0212733B8 (de)
CA (1) CA2462110C (de)
CO (1) CO5580746A2 (de)
CY (3) CY1107924T1 (de)
DE (2) DE60225162T3 (de)
DK (2) DK1749818T3 (de)
EA (2) EA007537B3 (de)
EG (1) EG25095A (de)
ES (2) ES2298425T7 (de)
FR (1) FR14C0033I2 (de)
HK (1) HK1072600A1 (de)
HR (1) HRP20040220A2 (de)
HU (3) HU230189B1 (de)
IL (1) IL160655A0 (de)
IS (2) IS2578B (de)
LT (1) LTC1436271I2 (de)
LU (1) LU92397I2 (de)
ME (1) ME00039B (de)
MX (1) MXPA04002959A (de)
MY (1) MY140950A (de)
NL (1) NL300652I2 (de)
NO (3) NO326443B1 (de)
NZ (1) NZ531556A (de)
PL (2) PL209253B1 (de)
PT (2) PT1749818E (de)
RS (2) RS52865B (de)
SI (1) SI1436271T1 (de)
UA (2) UA81749C2 (de)
WO (1) WO2003029232A1 (de)
ZA (1) ZA200401583B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
PT1635828E (pt) * 2003-04-04 2008-07-01 Lundbeck & Co As H Derivados de 4-(2-feniloxifenil) piperidina ou de 1,2,3,6-tetrahidropiridina como inibidores da recaptação da serotonina
MXPA05009592A (es) 2003-04-04 2005-10-18 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina.
CN1767829A (zh) * 2003-04-04 2006-05-03 H.隆德贝克有限公司 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物
NZ541859A (en) * 2003-04-04 2008-10-31 Lundbeck & Co As H 4-(2-Phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
PT1701940E (pt) 2003-12-23 2008-07-30 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-benzil-amina como ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) * 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
CN101472891B (zh) * 2006-06-16 2013-08-21 H.隆德贝克有限公司 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
AR061481A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a
BRPI0712758A2 (pt) * 2006-06-16 2012-09-25 H Lundbeck & Co As composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, método de tratamento de uma doença. e, uso do compsoto
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
ES2397247T3 (es) 2008-11-14 2013-03-05 Theravance, Inc. Forma cristalina de un compuesto 4-[2-(2-fluorofenoximetil)fenil]piperidina
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
EP2421534B1 (de) * 2009-04-24 2014-09-03 H. Lundbeck A/S Flüssige formulierungen von salzen von 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazin
KR20120065328A (ko) 2009-08-24 2012-06-20 하. 룬드벡 아크티에셀스카브 １-［２-（２,４-디메틸-페닐술파닐）-페닐］피페라진의 신규한 조성물
BR112012011443A2 (pt) * 2009-10-30 2020-09-08 Janssen Pharmaceutica N. V. fenilamina-2-fenóxi-4-substituída como moduladores do receptor delta opioide.
US8778949B2 (en) * 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
EP2550252B1 (de) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidin und piperazinverbindungen
MA34261B1 (fr) 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
DK3135656T3 (en) 2011-06-20 2019-04-23 H Lundbeck As DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
WO2013102573A1 (en) * 2012-01-03 2013-07-11 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
SG11201504483YA (en) 2012-12-13 2015-07-30 Lundbeck & Co As H Compositions comprising vortioxetine and donepezil
SI2958903T1 (sl) * 2013-02-22 2017-09-29 H. Lundbeck A/S Proizvodni proces za vortioksetin
CN105283442B (zh) * 2013-04-04 2018-04-13 斯洛文尼亚莱柯制药股份有限公司 用于合成1‑(2‑((2,4‑二甲基苯基)硫代)苯基)哌嗪的方法
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (de) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2-(Piperazin-1-yl)phenyl)lithium-Zwischenprodukte
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (de) 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2-(piperazin-1-yl)phenyl)anilin-Zwischenprodukte
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EA029060B1 (ru) 2014-01-31 2018-02-28 Эгиш Дьёдьсердьяр Зрт. Способ получения солей вортиоксетина
EP2930171A1 (de) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2,4-Dimethylphenyl) (2-Iodophenyl)sulfan-Zwischenprodukt
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
US10227317B2 (en) 2015-02-25 2019-03-12 Lupin Limited Process for the preparation of vortioxetine
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3799873A1 (de) 2015-07-17 2021-04-07 Institut Pasteur 5-hydroxytryptamin-1b-rezeptor-stimulierendes mittel zur verwendung als promoter von satellitenzellenselbsterneuerung und/oder -differenzierung
EP3337789A1 (de) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Verfahren zur herstellung von vortioxetinhydrobromid
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
AU2017295038B2 (en) * 2016-07-15 2022-09-22 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for skin and/or hair repair
JP2019523256A (ja) * 2016-07-22 2019-08-22 ジアンス・エンファルオカン・ファーマスーティカル・リサーチ・アンド・デベロップメント・カンパニー・リミテッドＪｉａｎｇｓｕ Ｎｈｗａｌｕｏｋａｎｇ Ｐｈａｒｍｃｅｕｔｉｃａｌ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．，Ｌｔｄ． ボルチオキサチン類似化合物、その用途及びその製造
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
US11020390B2 (en) 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
AU2018258947C1 (en) * 2017-04-25 2021-08-26 H. Lundbeck A/S Process for the manufacture of vortioxetine HBr alpha-form
EP3412661A1 (de) 2017-06-08 2018-12-12 Enantia, S.L. Co-kristalle von vortioxetin-hydrobromid und resorcin
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
JP7389761B2 (ja) 2018-06-20 2023-11-30 バイオ アーゲー ファーマシューティカルズ エス．エー． ボルチオキセチンおよびボルチオキセチン中間体を調製するためのワンポット有機擬触媒ｃ－ｈ活性化手法
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
KR20220163997A (ko) 2020-04-03 2022-12-12 하. 룬드벡 아크티에셀스카브 정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (de) 1971-04-13 1973-11-19
CS151755B1 (de) 1971-04-13 1973-11-19
CS151752B1 (de) 1971-04-13 1973-11-19
CS151753B1 (de) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
HU226635B1 (en) 1995-01-23 2009-05-28 Asubio Pharma Co Piperidine and piperazine derivatives, medicines containing them as active ingredient and their use
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU754656B2 (en) * 1997-10-31 2002-11-21 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
SK14022001A3 (sk) 1999-04-02 2002-03-05 Icos Corporation Inhibítory väzby LFA-1 na ICAM a ich použitie
EP1204645A2 (de) 1999-08-04 2002-05-15 Millennium Pharmaceuticals, Inc. An den melanocortin-4-rezeptor bindende verbindungen und verfahren ihrer verwendung
US6644364B1 (en) * 1999-09-14 2003-11-11 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
EP1246816B1 (de) * 1999-12-30 2004-03-17 H. Lundbeck A/S Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
AU2351701A (en) * 1999-12-30 2001-07-16 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
WO2002059117A1 (en) * 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2003053942A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
MXPA05009592A (es) * 2003-04-04 2005-10-18 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AR061481A1 (es) * 2006-06-16 2008-08-27 Lundbeck & Co As H Compuestos con actividad combinada sobre sert, 5-ht3 y 5-ht1a

Also Published As

Publication number Publication date
US20160137620A1 (en) 2016-05-19
BR122012009534B1 (pt) 2018-02-27
AU2006215994B2 (en) 2008-11-13
EA200601269A1 (ru) 2007-02-27
SI1436271T1 (sl) 2008-06-30
EP1749818A3 (de) 2008-04-02
JP2007051149A (ja) 2007-03-01
IS2578B (is) 2010-02-15
DE60225162D1 (de) 2008-04-03
MEP6508A (xx) 2010-02-10
KR20040047886A (ko) 2004-06-05
BR122012023120B1 (pt) 2017-03-21
KR100770194B1 (ko) 2007-10-25
HUS1400012I1 (hu) 2020-12-28
BE2014C036I2 (de) 2021-11-22
PT1436271E (pt) 2008-04-10
JP3896116B2 (ja) 2007-03-22
DE60233608D1 (de) 2009-10-15
RS27704A (en) 2006-10-27
EP1436271B3 (de) 2022-04-20
EA007537B1 (ru) 2006-10-27
EA200400498A1 (ru) 2004-08-26
EP1436271A1 (de) 2004-07-14
FR14C0033I2 (fr) 2014-11-14
NL300652I1 (de) 2016-01-18
US20140163043A1 (en) 2014-06-12
PL209253B1 (pl) 2011-08-31
US9708280B2 (en) 2017-07-18
IS2732B (is) 2011-04-15
PL210551B1 (pl) 2012-02-29
IS7164A (is) 2004-02-26
US20060089368A1 (en) 2006-04-27
HU228956B1 (en) 2013-07-29
US20070060574A1 (en) 2007-03-15
HK1072600A1 (en) 2005-09-02
JP2007031447A (ja) 2007-02-08
AU2006215994A1 (en) 2006-10-05
US20210276966A1 (en) 2021-09-09
ZA200401583B (en) 2005-05-25
US9090575B2 (en) 2015-07-28
NO2014011I1 (no) 2014-05-13
KR100783346B1 (ko) 2007-12-07
DK1436271T6 (da) 2022-06-27
AU2006215994A2 (en) 2006-10-05
PL368442A1 (en) 2005-03-21
BR122012023120B8 (pt) 2022-01-18
EA011096B1 (ru) 2008-12-30
NO332355B1 (no) 2012-09-03
BR122012009534B8 (pt) 2019-01-29
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
ME00039B (me) 2010-06-10
US20050014740A1 (en) 2005-01-20
EP1436271B1 (de) 2008-02-20
BR0212733B1 (pt) 2014-05-13
DK1436271T3 (da) 2008-06-09
EP1749818A2 (de) 2007-02-07
ES2298425T7 (es) 2022-06-27
CY2014022I1 (el) 2015-12-09
RS20120158A2 (en) 2012-10-31
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
HRP20040220A2 (en) 2005-02-28
AU2002333220A2 (en) 2003-04-14
NO20083446L (no) 2004-04-21
KR100842702B1 (ko) 2008-07-01
US20060084662A1 (en) 2006-04-20
CY1107924T1 (el) 2013-09-04
KR20060118020A (ko) 2006-11-17
AU2006215994A9 (en) 2006-10-05
NO2014011I2 (no) 2015-08-31
AR036659A1 (es) 2004-09-22
MY140950A (en) 2010-02-12
AU2002333220B2 (en) 2008-02-07
NL300652I2 (de) 2016-01-18
DE60225162T2 (de) 2009-02-12
PT1749818E (pt) 2009-10-06
US7683053B2 (en) 2010-03-23
CA2462110E (en) 2003-04-10
US7138407B2 (en) 2006-11-21
US20110009423A1 (en) 2011-01-13
NO326443B1 (no) 2008-12-08
US20120302553A1 (en) 2012-11-29
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
CA2462110C (en) 2010-05-11
US8476279B2 (en) 2013-07-02
ES2298425T3 (es) 2008-05-16
IL160655A0 (en) 2004-07-25
MXPA04002959A (es) 2004-07-05
EA007537B3 (ru) 2015-02-27
JP2005505585A (ja) 2005-02-24
EP1749818B1 (de) 2009-09-02
ES2328725T3 (es) 2009-11-17
AR066460A2 (es) 2009-08-19
CN1561336A (zh) 2005-01-05
JP3955613B2 (ja) 2007-08-08
CA2462110A1 (en) 2003-04-10
CO5580746A2 (es) 2005-11-30
DK1749818T3 (da) 2009-10-12
JP3955614B2 (ja) 2007-08-08
RS52865B (en) 2013-12-31
US7144884B2 (en) 2006-12-05
NO20041628L (no) 2004-04-21
BRPI0212733B8 (pt) 2021-05-25
CN1319958C (zh) 2007-06-06
AU2002333220C1 (en) 2023-10-05
LTC1436271I2 (lt) 2016-09-12
US20180127389A1 (en) 2018-05-10
HU230189B1 (hu) 2015-09-28
BR0212733A (pt) 2004-11-16
US7148238B2 (en) 2006-12-12
UA93857C2 (uk) 2011-03-25
US10844029B2 (en) 2020-11-24
WO2003029232A1 (en) 2003-04-10
UA81749C2 (uk) 2008-02-11
IS8806A (is) 2009-03-10
CY1110064T1 (el) 2015-01-14
ATE386730T1 (de) 2008-03-15
HUP0402313A3 (en) 2010-03-29
FR14C0033I1 (de) 2014-06-13
KR20070103515A (ko) 2007-10-23
CY2014022I2 (el) 2015-12-09
EG25095A (en) 2011-08-17
RS20120158A3 (en) 2013-10-31
HUP0402313A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK1515969T3 (da) Spiroindolinpiperidinderivater
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
IS7138A (is) Alkýn-arýl fosfódíesterasa-4 hindrar
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
DE60106252D1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE454381T1 (de) Benzofuranderivat
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
NO20035248D0 (no) Nye fenylalkyloksy-fenyl derivater
DE60201463D1 (de) Indanon-Derivate als Duftstoffe

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1749818

Country of ref document: EP